about
Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.Differential regulation of miR-21 and miR-146a by Epstein-Barr virus-encoded EBNA2.The Inescapable Influence of Noncoding RNAs in Cancer.Geographic Population Structure in Epstein-Barr Virus Revealed by Comparative GenomicsEpstein-Barr virus (EBV) positive classical Hodgkin lymphoma of Iraqi children: an immunophenotypic and molecular characterization of Hodgkin/Reed-Sternberg cells.Epigenetic mechanisms do not control viral latency III in primary effusion lymphoma cells infected with a recombinant Epstein-Barr virus.Mycobacterium tuberculosis-induced miR-155 subverts autophagy by targeting ATG3 in human dendritic cells.MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.Non-coding RNA networks in cancer.MicroRNAs in Autoimmunity and Hematological MalignanciesMalicious exosomesInfection of cell lines derived from diffuse large B-cell lymphoma (DLBCL) with the Epstein-Barr virus (EBV) alters the miRNA loading of the Ago2-complexEpstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomasOverexpression of miR-9 in the Nucleus Accumbens Increases Oxycodone Self-Administration.MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanismThe Nefarious Nexus of Noncoding RNAs in CancerSex-Dependent Changes in miRNA Expression in the Bed Nucleus of the Stria Terminalis Following StressMolecular networks in Network Medicine: Development and applicationsHypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccineHydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In VivoMiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
P50
Q35848490-96152DED-DF12-4152-84E5-7137529944D5Q39036600-790E053D-73B6-46AD-8667-ACCDFAC27239Q39344864-EF980C54-5EE7-4F8F-86D0-F91868ECBC84Q39927058-3A02342A-35B5-44FE-98D0-FE9A96D8A766Q40446900-11575E25-5168-495F-B6BD-DDF2C461525BQ42272470-33FF7E83-66E7-4350-BFAC-FAC9322DA4B9Q45428861-839BF2DD-A44A-4261-B8A9-852D8B470966Q47200738-6384E8CB-A7CC-4C8E-82D9-D6B29D18111BQ47726182-3EE30F14-4778-45A4-97D7-3D71FD3CCFEDQ49689803-57403261-2D55-4808-BC8D-D5E866BA44A2Q57471217-FD010BE1-96E9-450F-ADEA-4FEDCBE83BF2Q57631447-99DC6610-9ACA-45D1-801C-4041A248FA62Q59350990-121B6347-9390-4D30-BB60-459292E83015Q59358094-2EE645D7-8E49-48C2-BB97-6DE3DC5A4516Q64898514-C5A504A6-CC2E-4A3C-8365-6D5F35A603C3Q88675410-95DE9EA2-8E74-42B4-99D3-97870E80ADCAQ90293326-BA4ED5B4-AEE4-4B4B-ADF6-A322DF487209Q90860556-659504A6-BE20-4F6A-B10F-2CD785BB96F9Q92056159-F1E66A5D-9125-422F-B8C1-AC551A9680F4Q92091391-2AF89E1A-E43B-4D2A-B833-EEE7EEC0537DQ92121730-B8ACE035-3FDC-48C2-9AEF-92E606EEDA4DQ92392839-F3F3E37B-0969-4707-8E79-527FBCE91C63
P50
description
researcher ORCID id 0000-0003-0212-6734
@en
wetenschapper
@nl
name
Eleni Anastasiadou
@ast
Eleni Anastasiadou
@en
Eleni Anastasiadou
@es
Eleni Anastasiadou
@nl
type
label
Eleni Anastasiadou
@ast
Eleni Anastasiadou
@en
Eleni Anastasiadou
@es
Eleni Anastasiadou
@nl
altLabel
ELENI ANASTASIADOU
@en
prefLabel
Eleni Anastasiadou
@ast
Eleni Anastasiadou
@en
Eleni Anastasiadou
@es
Eleni Anastasiadou
@nl
P106
P1153
8968408000
P31
P496
0000-0003-0212-6734